<DOC>
	<DOCNO>NCT00295828</DOCNO>
	<brief_summary>The purpose study determine drug call Macugen may help stop growth abnormal blood vessel iris occur eye ( ) part diabetic retinopathy .</brief_summary>
	<brief_title>A Pilot Study Treatment Iris Neovascularization With Macugen</brief_title>
	<detailed_description>Diabetic retinopathy eye condition cause diabetes new blood vessel grow retina ( back , inside part eye ) iris . These vessel normal may leak break , cause bleed eye . This process lead vision loss blindness , glaucoma ( disease eye eye pressure usually high result damage optic nerve ) , eye problem . This study determine drug call Macugen may help stop growth abnormal blood vessel iris .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female , least 18 year age 2 . Diabetic retinopathy iris neovascularization 3 . Visual acuity must light perception well study eye 4 . Female patient childbearing potential must negative urine pregnancy test screen visit . 5 . Written inform consent obtain 6 . Written authorization use release health research study information obtain Exclusion criterion : 1 . Neovascular glaucoma ( difficult form glaucoma control lead painful eye high intraocular pressure , corneal swelling , `` cell flare '' anterior chamber . Caused abnormal new blood vessel formation ( neovascularization ) iris , extend trabecular meshwork cause closure angle drainage structure ) . 2 . No light perception study eye . 3 . Inadequate view retina PRP/angiography 4 . Anterior chamber intraocular lens implant 5 . PRP treatment past 60 day . Patients may participate PRP treatment beyond 60 day newly diagnose NVI nonregression previously diagnose NVI . 6 . Previous current Macugen use 7 . Any active ocular infection 8 . Any condition preclude patient ability comply study requirement include completion study 9 . Female patient pregnant , nursing , plan pregnancy , childbearing potential use reliable mean contraception 10 . Current enrollment investigational drug device study participation study within 30 day prior screen 11 . Patient condition situation , investigator 's opinion , may put patient significant risk , may confound study result may interfere significantly patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>VEGF</keyword>
	<keyword>iris neovascularization</keyword>
	<keyword>diabetic retinopathy</keyword>
	<keyword>Macugen</keyword>
</DOC>